Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of... Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen.
- Mechanism
- Curator reviewed
Batroxobin is a thrombin like serine protease enzyme that will cleave fibrinogen. Cleavage at the16 Arginine - 17 Glycine bond in the A alpha chain of fibrinogen releases fibrinopeptide A and forms a fibrin I monomer that will spontaneously aggregate into a clot. The reduction of plasma fibrinogen by formation of fibrin microclots that are easily cleared by the reticuloendothelial system can decrease high blood viscosity which contributes to the formation of thromboemboli.
In addition, batroxobin is reported to induce fibrinolysis by inducing the endothelial release of tissue plasminogen activator (tPA) from vascular endothelial cells. This effect may potentially be dose dependant.
- Primary indication
- No approved indications.Curator reviewed
- Also known as
- Bothrops atrox blood-coagulation factor X activator
- Code names
- DF-521
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with Batroxobin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account